Scoop: Google’s GV spear­heads the Spot­light syn­di­cate — back­ing an up­start biotech aimed at ‘de­moc­ra­tiz­ing’ gene edit­ing

CRISPR had no soon­er start­ed to shake the very foun­da­tions of drug de­vel­op­ment be­fore its lim­i­ta­tions be­gan to loom large. Gene edit­ing could change the world — if on­ly you could get around the hur­dles that threat­ened to trip up every pro­gram.

So it’s on­ly nat­ur­al to see CRISPR 2.0 tak­ing shape be­fore the pi­o­neers can get the lead ther­a­pies through de­vel­op­ment. And who bet­ter than Google’s GV ven­ture arm to take the lead spot in a small syn­di­cate back­ing some sci­en­tists with their own unique twist on a so­lu­tion?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.